CD19 and acute lymphoblastic leukemia: The therapeutic potential of this approach is exemplified by Blinatumomab (Blincyto), a bispecific T cell engager (BiTE) targeting CD19 which showed significantly longer OS than chemotherapy group in relapsed or refractory B-cell precursor ALL [11].